HURN Q1 2026: Revenue Rises, Net Income Dips, Share Buybacks Boost EPS

Lead insight

Huron (Nasdaq: HURN) delivered its first-quarter 2026 results with a clear signal: top-line growth is fueling momentum, even as net income takes a small step back. Revenues before reimbursable expenses (RBR) climbed to $443.7 million, a 12.1% year-over-year increase, while the firm reiterated its full-year 2026 outlook. Diluted EPS rose to $1.34 from $1.33 a year ago, aided by a meaningful share repurchase that shaved the denominator and pushed per-share results higher, despite a decline in net income to $23.2 million from $24.5 million in Q1 2025. The press release also flags a notable lift in Adjusted EBITDA and a record RBR in the Healthcare segment, underscoring the mix shift within the firm's professional-services portfolio.

In short: you get more revenues, you get a tighter float, and you get a reaffirmed revenue forecast—but you don’t necessarily get a clean beat on the bottom line. The document does not present an explicit earnings surprise versus a published EPS consensus, opting instead to emphasize guidance, cash-return to shareholders, and non-GAAP metrics like Adjusted EBITDA.

Quarter in numbers

• Revenues before reimbursable expenses (RBR): $443.7 million, up 12.1% YoY
• Net income: $23.2 million, vs. $24.5 million in Q1 2025
• Adjusted EBITDA: $50.6 million, up 21.9% from $41.5 million
• Diluted EPS: $1.34, up from $1.33
• Adjusted diluted EPS: $1.73, up from $1.68
• Share repurchase: $155.5 million, 1.1 million shares bought back (6.5% of outstanding as of 12/31/2025)
• Guidance: reaffirmed full-year 2026 RBR in a range of $1.78 billion to $1.86 billion
• Strategic notes: Healthcare posted a record RBR; growth across Healthcare, Education, and Commercial segments
• Non-GAAP framing: the company continues to highlight Adjusted EBITDA as a measure of operating performance

Where the growth is coming from

The release emphasizes a diversified demand backdrop, with Healthcare leading the charge in RBR growth and Education and Commercial segments contributing to the gains. While the headline numbers center on revenue expansion, the earnings story hinges on cost management, mix shifts, and the impact of stock repurchases on per-share metrics. The press release also notes a continuing emphasis on talent and culture, highlighted by a Great Place To Work certification in multiple regions, underscoring the company’s strategy to sustain advisory capacity in a competitive talent market.

Guidance and outlook

Guidance remains intact for full-year 2026, with RBR projected in a $1.78–$1.86 billion band. That reaffirmation matters in a landscape where investors weigh scale, utilization, and pricing discipline across professional-services practices. The persistence of a sizable buyback program—returning cash to shareholders via repurchases—supports EPS enhancement and capital structure flexibility, even as net income shows a modest year-over-year dip.

Analysis: what this portends for HURN and peers

On the surface, the quarter reads like a company leaning into growth levers: higher RBR, disciplined capital returns, and a reassuring reaffirmation of 2026 targets. The per-share improvement in EPS is largely a function of a smaller share count, courtesy of the buyback, rather than a surge in net income. That dynamic is a familiar feature in advisory-heavy firms where buybacks can lift EPS even when net income is flat or slightly down.

For sector peers, the message is twofold. First, a diversified services mix—especially a standout Healthcare RBR—can coexist with meaningful cash returns to shareholders. Second, non-GAAP metrics like Adjusted EBITDA continue to contribute to the narrative of operating performance independent of reimbursable expense accounting. Investors will watch whether Healthcare momentum sustains or accelerates, given its outsized impact on the quarterly top line, and whether Education and Commercial demand can keep pace as budgets tighten in some client bases.

As for the broader market sentiment, the absence of an explicit earnings surprise or a disclosed EPS consensus in the release means the stock will likely trade on the combination of topline momentum, margin management, and the optics of capital returns. In other words, the punchline isn’t a home-run beat; it’s a deliberate, steadier step forward with a focus on execution and capital discipline.

Implications for peers and the competitive landscape

Peers in the professional-services space may view HURN’s Q1 as a benchmark for balancing growth with cash returns. Firms that can translate revenue growth into per-share value through buybacks—especially when net income lags slightly—could see similar investor appeal. In markets where Healthcare-driven demand is a differentiator, the ability to sustain a record RBR in that segment may become a more explicit differentiator among peers seeking to defend pricing power and client stickiness.

Bottom line

Huron’s Q1 2026 results sketch a company that can grow revenue, manage its cost structure, and deploy capital to bolster per-share metrics while reaffirming its long-range plan. The combination of a robust healthcare top line, continued demand across segments, a tangible buyback program, and a reaffirmed RBR guidance provides a roadmap for analysts weighing HURN against sector equivalents. For now, the stock may lean on a steady-as-she-goes narrative, with the potential for a more pronounced re-rating if Healthcare momentum translates into sustained margin gains and a clean comparative EPS beat in upcoming quarters.

Disclosure and contacts

The press release includes standard investor and media contact information and notes that the firm has been certified by Great Place To Work in multiple regions. As with any earnings release, market interpretation will hinge on subsequent quarterly results and how the company navigates margin progression alongside continued top-line growth.